Tongyuan Kang Pharmaceuticals: Reached a licensing and cooperation agreement with Qilu.

According to the announcement of Tongyuan Kang Pharmaceuticals, the company has reached a licensing and cooperation agreement with Qilu or its designated affiliate, as well as a supply and commercialization agreement, to cooperate in the development, production, and commercialization of cooperative APIs in China, as well as TY-9591. Under the licensing and cooperation agreement, the company will receive a total of approximately 700 million RMB as an upfront payment, including approximately 400 million RMB from the subscription agreement and potential milestone payments. In addition, the company has also entered into a supply and commercialization agreement with Qilu, with a term of three years and renewable.